论文部分内容阅读
目的观察地特胰岛素治疗24周对2型糖尿病(T2DM)肥胖及非肥胖患者血糖及体重的影响。方法选取既往未接受过胰岛素治疗的T2DM患者54例,根据BMI分为肥胖(Ob)组24例和非肥胖(NOb)组30例,检测治疗前后体重、FBG、HbA_1c,计算BMI、胰岛素用量等。结果地特胰岛素治疗24周后,Ob组和NOb组FBG[(7.3±1.2)mmol/L、(6.7±1.5)mmol/L]、HbA_1c[(7.3±0.9)%、(6.5±0.8)%]均较基线值{FBG[(9.4±2.5)mmol/L、(8.1±1.7)mmol/L]、HbA_1c[(8.2±1.1)%、(7.6±1.9)%]}明显下降(P<0.05);Ob组治疗前后BMI变化[(-1.51±1.10)kg/m~2]与NOb组[(0.15±1.00)kg/m~2]比较,差异有统计学意义(P<0.05)。结论地特胰岛素治疗可有效降低肥胖和非肥胖T2DM患者血糖,且无明显体重增加效应。
Objective To observe the effects of detemir treatment for 24 weeks on the blood sugar and body weight of obese and non-obese patients with type 2 diabetes mellitus (T2DM). Methods Totally 54 patients with T2DM who did not receive insulin therapy were enrolled in this study. According to BMI, 24 patients in ob group and 30 patients in non-obese group were enrolled in the study. Body weight, FBG, HbA_1c, BMI and insulin dosage . Results After 24 hours of insulin treatment, FBG [(7.3 ± 1.2) mmol / L, (6.7 ± 1.5) mmol / L], HbA_1c [(7.3 ± 0.9)%, (6.5 ± 0.8) ] Were significantly lower than baseline values (FBG [(9.4 ± 2.5) mmol / L, (8.1 ± 1.7) mmol / L] and HbA_1c [(8.2 ± 1.1)%, (7.6 ± 1.9)%] ); The change of BMI in ob group before and after treatment [(-1.51 ± 1.10) kg / m 2] was significantly different from that in NOb group (0.15 ± 1.00 kg / m 2) (P 0.05). Conclusion Detemir insulin treatment can effectively reduce blood glucose in obese and non-obese T2DM patients with no significant weight gain.